Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: An in vitro comparison

Indian Journal of Ophthalmology

Volumn 55, Issue 1, 2007, Pages 15-19

  Duggirala, Aparna ^a   Joseph, Joveeta ^a   Sharma, Savitri ^a   Nutheti, Rishita ^a   Garg, Prashant ^a   Das, Taraprasad ^a  

^a L V PRASAD EYE INSTITUTE   (India)

Author keywords

Fluoroquinolones; Gram negative bacteria; Gram positive bacteria; Minimum inhibitory concentration

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL EYE INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOPHTHALMITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STATISTICAL ANALYSIS;

EID: 33846045181     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.29489     Document Type: Article

References (23)

1. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for the treatment of bacterial keratitis. Am J Ophthalmol 1991;112:34S-47S.
2. Baum JL. Initial therapy of suspected microbial corneal ulcers. I Broad antibiotic therapy based on prevalence of organism. Surv Ophthalmol 1979;24:97-105.
3. Hynduik RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology 1996;103:1854-63.
4. Garg P, Sharma S, Rao GN. Ciprofloxacin- resistant Pseudomonas keratitis. Ophthalmology 1999;106:1319-23.
5. Goldstein M, Kowalski RP, Gordon YJ. Emerging fluoroquinolones resistance in bacterial keratitis. Ophthalmology 1999;106:1313-8.
6. Sharma V, Sharma S, Garg P, Rao GN. Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy. Indian J Ophthalmol 2004;52:287-92.
7. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: An evidence based update. Ophthalmology 2002;109:13-24.
8. Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: A 6-year a review of culture proven cases. Am J Ophthalmol 2004;137:38-42.
9. Kowalski RP, Pandya AN, Karenchak LM, Romanowski EG, Husted RC, Ritterband DC, et al. An in vitro resistance study of levofloxacin, ciprofloxacin and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology 2001;108:1826-9.
10. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratits in South Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107:1497-502.
11. Chaudhry NA, Flynn HW, Murray TG, Homayoun T, Mello MO Jr, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999;128:509-10.
12. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic Antibiotics. Am J Ophthalmol 2002;133:463-6.
13. Kowalski RP, Deepinder KD, Lisa MK, Romanowski EG, Francis S, Ritterband DC, et al. Gatifloxacin and Moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-5.
14. Callegan MC, Ramirez R, Kane ST, Cochran DC, Jensen H. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens. Adv Ther 2003;20:246-52.
15. Gerri SH, Sharon P. Use of the concentration gradient diffusion assay (E test) for susceptibility testing of Anaerobes, Fungi and Mycobacterium spp. Clin Microbiol Newsletter 2002;24:105-9.
16. E test. AB BIODISK. Solna: Sweden etest@abbiodisk.
17. Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999;58:37-42.
18. Hawang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49:S79-83.
19. Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 2005;122:466-9.
20. Srinivasan M, Gonzales CA, George C, Cevallos V, Mascarenhas JM, Asokan B, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol 1997;81:965-71.
21. Ormerod LD, Hertzmark E, Gomez DS, Stabiner RG, Schanzlin DJ, Smith RE. Epidemiology of microbial keratitis in southern California. A multivariate analysis. Ophthalmology 1987;94:1322-33.
22. Stroman DW, Clark L, Macke L, Mendoza B, Schlech, Brien TO. Moxifloxacin activity against quinolone resistant staphylococcal ocular isolates. Invest Ophthalmol Vis Sci 2001;42:1377.
23. Swailto E, Moore E, Watt J, Mc Daniel LS. In vitro activity of four fluoroquinolones against clinical isolates of Pseudomonas aeruginosa determined by the E test. Int J Antimicrob Agents 2000;15:73-6.